Skip to main content

Dr. Rohit Kumar, M.D.

Hematology & Oncology (Hematology & Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
14
In the NPI registry since
2014
Medicare patients seen, 2024
284

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2014Registered with an NPI (national billing number; not a license date)

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology & Oncology Physician primary
    KY license 51209
  • Hospice and Palliative Medicine (Internal Medicine) Physician
    AR license NA
  • Internal Medicine Physician
    IL license 125065724

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology & Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
284
Services billed
1,025
Patients’ average age
72
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 30-39 minutes303114
Established patient office or other outpatient visit, 40-54 minutes18865
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes14457
New patient office or other outpatient visit, 60-74 minutes6060
Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes4342
Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes3332
Established patient office or other outpatient visit, 20-29 minutes3226
New patient office or other outpatient visit, 45-59 minutes3030
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes2724

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Abiraterone Acetate180
Prednisone
Other prescribers in Louisville, KY
155
Oxycodone Hcl
Other prescribers in Louisville, KY
114
Xtandi (enzalutamide)96
Cabometyx (cabozantinib s-malate)59
Potassium Chloride
Other prescribers in Louisville, KY
54
Dexamethasone
Other prescribers in Louisville, KY
50
Prochlorperazine Maleate
Other prescribers in Louisville, KY
38
Orgovyx (relugolix)36
Nubeqa (darolutamide)35

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 30 companies reported 125 payments worth $13,987 in total to this clinician.

By company
Pfizer Inc.$4,290
EMD Serono, Inc.$2,862
Springworks Therapeutics, Inc.$2,253
AstraZeneca Pharmaceuticals LP$1,472
Deciphera Pharmaceuticals Inc.$1,110
Daiichi Sankyo Inc.$413
Novartis Pharmaceuticals Corporation$220
Celgene Corporation$179
By type
Consulting Fee$7,048
Compensation for services other than consulting (speaking, faculty)$3,275
Food and Beverage$2,555
Honoraria$1,110

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Nov 18, 2025Pfizer Inc.
Nov 18, 2025
Compensation for services other than consulting (speaking, faculty)
TALZENNA · ONCOLOGY
$3,275
Oct 6, 2025EMD Serono, Inc.
Oct 6, 2025
Consulting Fee
Company’s descriptionAdvisory Board Participation (Fee For Service)
$2,820
May 16, 2025Springworks Therapeutics, Inc.
May 16, 2025
Consulting Fee
OGSIVEO · DESMOID TUMORS
$2,188
Jun 18, 2025AstraZeneca Pharmaceuticals LP
Jun 18, 2025
Consulting Fee
IMFINZI · Oncology
$1,340
Mar 10, 2025Deciphera Pharmaceuticals Inc.
Mar 10, 2025
Honoraria
VIMSELTINIB · ONCOLOGY
$1,110
May 7, 2025Pfizer Inc.
May 7, 2025
Consulting Fee
TALZENNA · ONCOLOGY
$700

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Kentucky →

Industry-funded research

Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $546,276 in research payments for these studies, mostly to the institutions running them.

  • A Phase 2a Study with Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Tumors
    Merck Sharp & Dohme LLC
  • A phase 3 randomized openlabel study of PF06821497 mevrometostat in combination with enzalutamide compared with enzalutamide or docetaxel in participants with metastatic castration resistant prostate cancer previously…
    Pfizer Inc.
  • A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab MK-3475 Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Blad…
    Merck Sharp & Dohme LLC
  • A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With …
    Amgen Inc.
  • A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4)
    Janssen Research & Development, LLC

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Louisville

Sources

NPI registry (CMS NPPES, November 2026; record last updated April 12, 2021), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1154737724. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.